CONMED Corporation Company Profile (NASDAQ:CNMD)

CONMED Corporation trades on the NASDAQ under the ticker symbol "CNMD."

CONMED Corporation announced a quarterly dividend on Tuesday, August 29th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.20 per share on Thursday, October 5th. This represents a $0.80 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date is Thursday, September 14th. View CONMED Corporation's Dividend History.

CONMED Corporation (NASDAQ:CNMD) announced its quarterly earnings data on Wednesday, July, 26th. The company reported $0.41 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.41. The firm had revenue of $197.20 million for the quarter, compared to analysts' expectations of $194.50 million. CONMED Corporation had a return on equity of 8.38% and a net margin of 2.02%. The firm's revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 earnings per share. View CONMED Corporation's Earnings History.

CONMED Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for CONMED Corporation.

CONMED Corporation issued an update on its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $1.85-1.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.86.

4 brokerages have issued 1-year price objectives for CONMED Corporation's shares. Their predictions range from $43.00 to $57.00. On average, they expect CONMED Corporation's share price to reach $49.33 in the next year. View Analyst Ratings for CONMED Corporation.

Here are some recent quotes from research analysts about CONMED Corporation stock:

• 1. According to Zacks Investment Research, "Over the past three months CONMED Corporation has outperformed the broader industry trends in terms of price performance. CONMED offers a broad line of surgical products. The company’s product pipeline consists of several new devices including new sports medicine products,  endomechanical offerings, a new electrosurgical council and the latest 2D Arthroscopy video system. With increased product offerings, the company can accelerate its top line. The company has recently registered strong second-quarter results wherein adjusted earnings beat the Zacks Consensus Estimate, while revenues also did the same. On the flipside, foreign exchange movements have been unfavorably impacting the company’s results of late. Additionally, the company operates in a highly competitive environment which is likely to mar the top-line growth. Furthermore, a falling estimate revision trend for the current year indicates looming concerns ahead of the stock." (7/28/2017)
• 2. Needham & Company LLC analysts commented, "CNMD’s 1Q17 revenue and EPS beat consensus and management maintained its 2017 guidance. Importantly, CNMD’s revenue growth (arguably the most important metric at this point) improved to 3.7% CC in 1Q17 from (1.5%) CC in 4Q16. This is the highest organic growth CNMD has seen in the past six years. While comps get a bit more difficult in the next few quarters, new products (particularly in the Orthopedic Surgery business) should begin to meaningfully contribute to growth by 2H17." (4/27/2017)
• 3. Leerink Swann analysts commented, "We remain cautious on the company’s ability to manage through what we believe could be meaningful top-line headwinds in F2H17 and FY2018 in order to return to and sustain a solid mid- single-digit growth trajectory after just 3% growth in F2Q17, including: (1) A competitive CRM (cardiac rhythm management) product cycle, (2) Current and upcoming competitive launches in DES (drug eluting stents), (3) Potential modest share loss in U.S. TAVR (transcatheter aortic valve replacement) with a competitor recently receiving an expanded indication that is likely ~12-18 months ahead of MDT only partially offset by MDT’s recent large valve size launch; and (4) Continued share loss in Neuromodulation, particularly in SCS (spinal cord stimulation), DBS (deep brain stimulation), and implantable drug infusion pumps." (11/23/2016)

Some companies that are related to CONMED Corporation include NuVasive (NUVA), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), MiMedx Group (MDXG), Asante Solutions (PUMP), OraSure Technologies (OSUR), Cardiovascular Systems (CSII), Orthofix International N.V. (OFIX), K2M Group Holdings (KTWO), Intersect ENT (XENT), AtriCure (ATRC), CryoLife (CRY), Landauer (LDR), Meridian Bioscience (VIVO), Transenterix (TRXC) and Transenterix (TRXC).

CONMED Corporation's management team includes the folowing people:

• Mark E. Tryniski, Independent Chairman of the Board
• Curt R. Hartman, President, Chief Executive Officer, Director
• Luke A. Pomilio, Chief Financial Officer, Executive Vice President - Finance
• Patrick J. Beyer, President of CONMED International
• Daniel S. Jonas, Executive Vice President - Legal Affairs, General Counsel
• Heather L. Cohen, Executive Vice President - Human Resources, Secretary
• Wilfredo Ruiz-Caban, Executive Vice President - Quality Assurance, Regulatory Affairs and Operations
• Peter K. Shagory, Executive Vice President - Strategy and Corporate Development
• Nathan Folkert, Vice President, General Manager - U.S. Orthopedics Business
• John E. Kennedy, Vice President and General Manager - U.S. Endoscopic Technologies

Shares of CONMED Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CONMED Corporation stock can currently be purchased for approximately $52.39.